Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-01-13 12:00 |
Cantargia successfully concludes toxicity study with CAN10 antibody ahead of ph…
|
English | 184.7 KB | ||
| 2023-01-13 12:00 |
Cantargia slutför framgångsrikt toxicitetsstudie för CAN10-antikroppen inför an…
|
Swedish | 185.7 KB | ||
| 2023-01-13 11:33 | English | 36.0 KB | |||
| 2022-11-21 11:00 |
Valberedning utsedd inför årsstämman 2023
|
Swedish | 142.3 KB | ||
| 2022-11-21 11:00 |
Nomination Committee appointed ahead of 2023 Annual General Meeting
|
English | 143.8 KB | ||
| 2022-11-10 08:30 | Swedish | 739.5 KB | |||
| 2022-11-10 08:30 | English | 753.2 KB | |||
| 2022-11-08 16:00 |
Cantargias CAN10 visar positiva effekter i modeller av systemisk skleros i de n…
|
Swedish | 196.3 KB | ||
| 2022-11-08 16:00 |
Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models i…
|
English | 192.9 KB | ||
| 2022-11-07 14:00 |
Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising ant…
|
English | 199.3 KB | ||
| 2022-11-07 14:00 |
Cantargia presenterar nya data på SITC 2022 som stödjer nadunolimabs lovande kl…
|
Swedish | 197.8 KB | ||
| 2022-10-14 12:00 |
Cantargia når milstolpe i patientrekryteringen och fokuserar utvecklingen av na…
|
Swedish | 194.0 KB | ||
| 2022-10-14 12:00 |
Cantargia reaches recruitment milestone and focuses nadunolimab development on …
|
English | 193.8 KB | ||
| 2022-09-22 08:30 |
Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Ke…
|
English | 197.0 KB | ||
| 2022-09-22 08:30 |
Cantargia meddelar att första patienten med icke-skivepitel NSCLC behandlats me…
|
Swedish | 195.7 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
